2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
10 stocks we like better than Intellia Therapeutics › Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares lag the market significantly this year. Intellia's stock is down 19%, while Iovance's has dropped 61%. Some Wall Street analysts think these stocks are undervalued at current levels, though. Intellia's average price target of $22.43 (according to Yahoo! Finance) implies an upside of 139% from its current levels, while Iovance's $8.35 target implies that it could soar by 191%. Should investors purchase shares of either of these companies ahead of 2026? Intellia Therapeutics, a gene editing specialist, has encountered a clinical setback. One of the company's candidates, nex-z, was placed on clinical hold by regulatory authorities in the U.S. Nex-z is being developed as a potential treatment for transthyretin amyloidosis, a rare, prog
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTLA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 12/12/25 - Form 4
- 12/11/25 - Form 144
- 11/12/25 - Form SCHEDULE
- NTLA's page on the SEC website